Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis. (2023). SKIN The Journal of Cutaneous Medicine, 7(6), s271. https://doi.org/10.25251/skin.7.supp.271